CA2352702A1 - Novel human proton gated ion channel - Google Patents

Novel human proton gated ion channel Download PDF

Info

Publication number
CA2352702A1
CA2352702A1 CA002352702A CA2352702A CA2352702A1 CA 2352702 A1 CA2352702 A1 CA 2352702A1 CA 002352702 A CA002352702 A CA 002352702A CA 2352702 A CA2352702 A CA 2352702A CA 2352702 A1 CA2352702 A1 CA 2352702A1
Authority
CA
Canada
Prior art keywords
hasic1b
hasic1
polypeptide
sequence
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002352702A
Other languages
English (en)
French (fr)
Inventor
Philippe Seguela
Kazimierz Babinski
Naima Abadi
Stefano Catarsi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University filed Critical McGill University
Priority to CA002352702A priority Critical patent/CA2352702A1/en
Priority to JP2003514006A priority patent/JP2005505264A/ja
Priority to PCT/CA2002/001120 priority patent/WO2003008448A2/en
Priority to EP02750709A priority patent/EP1409680A2/en
Priority to CA002453655A priority patent/CA2453655A1/en
Priority to AU2002354842A priority patent/AU2002354842A1/en
Priority to US10/484,187 priority patent/US20050119458A1/en
Publication of CA2352702A1 publication Critical patent/CA2352702A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
CA002352702A 2001-07-18 2001-07-18 Novel human proton gated ion channel Abandoned CA2352702A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002352702A CA2352702A1 (en) 2001-07-18 2001-07-18 Novel human proton gated ion channel
JP2003514006A JP2005505264A (ja) 2001-07-18 2002-07-18 新規ヒトプロトンゲート調節チャンネル
PCT/CA2002/001120 WO2003008448A2 (en) 2001-07-18 2002-07-18 Novel human proton-gated channels
EP02750709A EP1409680A2 (en) 2001-07-18 2002-07-18 Novel human proton-gated channels
CA002453655A CA2453655A1 (en) 2001-07-18 2002-07-18 Novel human proton-gated channels
AU2002354842A AU2002354842A1 (en) 2001-07-18 2002-07-18 Novel human proton-gated channels
US10/484,187 US20050119458A1 (en) 2001-07-18 2002-07-18 Novel human proton-gated channels

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002352702A CA2352702A1 (en) 2001-07-18 2001-07-18 Novel human proton gated ion channel

Publications (1)

Publication Number Publication Date
CA2352702A1 true CA2352702A1 (en) 2003-01-18

Family

ID=4169435

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002352702A Abandoned CA2352702A1 (en) 2001-07-18 2001-07-18 Novel human proton gated ion channel

Country Status (6)

Country Link
US (1) US20050119458A1 (enExample)
EP (1) EP1409680A2 (enExample)
JP (1) JP2005505264A (enExample)
AU (1) AU2002354842A1 (enExample)
CA (1) CA2352702A1 (enExample)
WO (1) WO2003008448A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1532251A1 (en) * 2002-08-12 2005-05-25 Pfizer Inc. Human acid sensing ion channel 2b (hasic2b), process for producing the same, and its use
ES2886123T3 (es) 2012-01-31 2021-12-16 Regeneron Pharma Anticuerpos anti-asic1 y usos de los mismos
US9371383B2 (en) 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759373B1 (fr) * 1997-02-11 2001-05-04 Centre Nat Rech Scient Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
GB9718365D0 (en) * 1997-08-29 1997-11-05 Univ London Ion channel proteins

Also Published As

Publication number Publication date
AU2002354842A1 (en) 2003-03-03
WO2003008448A2 (en) 2003-01-30
EP1409680A2 (en) 2004-04-21
WO2003008448A3 (en) 2003-05-30
US20050119458A1 (en) 2005-06-02
JP2005505264A (ja) 2005-02-24

Similar Documents

Publication Publication Date Title
US5912144A (en) Edg-1-receptor homolog
US6503733B1 (en) Human anion channel
US6326207B1 (en) Human sodium-dependent phosphate cotransporter
US20030166847A1 (en) Novel human leptin receptor gene-related protein
US5856129A (en) DNA encoding a human purinoceptor
US7547521B2 (en) Heteromultimeric ion channel receptor and uses thereof
US6010859A (en) RAB protein
CA2301498A1 (en) New human g-protein coupled receptor
US20020169308A1 (en) Novel human membrane protein
US20050119458A1 (en) Novel human proton-gated channels
US20020161191A1 (en) Novel Imidazoline receptor homologs
CA2277084A1 (en) Human chloride channel protein (hccp)
US5919655A (en) Human phospholemman homolog
US20030087391A1 (en) B cell receptor associated proteins
CA2453655A1 (en) Novel human proton-gated channels
US6204372B1 (en) DNA encoding a human tubby homolog
US5955301A (en) Human glutamate-binding protein
CA2406660A1 (en) Heteromultimeric ion channel receptor and uses thereof
WO2004084810A2 (en) Novel imidazoline receptor homologs
WO2002050300A2 (en) Human hyperpolarization-activated cyclic nucleotide-gated cation channel hcn3

Legal Events

Date Code Title Description
FZDE Discontinued